Royalty Pharma PLC
NASDAQ:RPRX
Royalty Pharma PLC
NASDAQ:RPRX
Price:
27.27 USD
-2.19%
Market Closed
Updated:
May 18, 2024
Royalty Pharma PLC
EPS (Diluted)
|
Royalty Pharma PLC
EPS (Diluted) Peer Comparison
Comparables:
JNJ
BMY
PFE
MRK
LLY
Competitive EPS (Diluted) Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | EPS (Diluted) | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Royalty Pharma PLC
NASDAQ:RPRX
|
EPS (Diluted)
$1
|
CAGR 3-Years
13%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
N/A
|
|
|
Johnson & Johnson
NYSE:JNJ
|
EPS (Diluted)
$15
|
CAGR 3-Years
41%
|
CAGR 5-Years
24%
|
CAGR 10-Years
12%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
EPS (Diluted)
-$3
|
CAGR 3-Years
-3%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Pfizer Inc
NYSE:PFE
|
EPS (Diluted)
$0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Merck & Co Inc
NYSE:MRK
|
EPS (Diluted)
$0
|
CAGR 3-Years
-31%
|
CAGR 5-Years
-23%
|
CAGR 10-Years
-5%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
EPS (Diluted)
$6
|
CAGR 3-Years
0%
|
CAGR 5-Years
1%
|
CAGR 10-Years
7%
|
See Also
What is Royalty Pharma PLC's EPS (Diluted)?
EPS (Diluted)
1.9
USD
1.9
USD
Based on the financial report for Dec 31, 2023, Royalty Pharma PLC's EPS (Diluted) amounts to 1.9 USD.
What is Royalty Pharma PLC's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 5Y
-4%
-4%
Over the last year, the EPS (Diluted) growth was 1 780%. The average annual EPS (Diluted) growth rates for Royalty Pharma PLC have been 13% over the past three years , -4% over the past five years .
You don't have any saved screeners yet
